India, April 13 -- Spyre Therapeutics, Inc. (SYRE) shares surged 25.07 percent to $64.15, gaining $12.86 on Monday, after the company reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial evaluating SPY001 for ulcerative colitis.
The stock is currently trading at $64.15, up sharply from its previous close of $51.29 on the Nasdaq. It opened at $66.50 and has traded in a range of $59.02 to $75.00 during the session, with volume reaching 3.85 million shares compared to an average of 747,248 shares.
The company said SPY001 demonstrated promising efficacy and safety, supporting its potential as a best-in-class anti-a4ß7 therapy. Enrollment for Part A has been completed, with Part B now underway, and additional ...